Stockscreener 앱 받기
1.39
1.46%
0.02
전일 마감가:
$1.37
열려 있는:
$1.36
하루 거래량:
150.30K
Relative Volume:
0.25
시가총액:
$47.79M
수익:
-
순이익/손실:
$-16.14M
주가수익비율:
-2.5741
EPS:
-0.54
순현금흐름:
$-3.99M
1주 성능:
+2.21%
1개월 성능:
-0.71%
6개월 성능:
+20.87%
1년 성능:
-70.98%
1일 변동 폭
$1.355
$1.41
1주일 범위
$1.32
$1.41
52주 변동 폭
$1.12
$5.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
TELO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.39 | 47.10M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR) - Defense World
Gainers Report: What are the risks of holding Telomir Pharmaceuticals Inc2025 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Review & Low Risk Entry Point Tips - baoquankhu1.vn
Rodman & Renshaw initiates Telomir Pharma stock with Buy rating By Investing.com - Investing.com Canada
Aug Shorts: Is ImmuCell Corporation forming a bullish divergenceEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Telomir Pharmaceuticals Received Notice of Noncompliance - TradingView — Track All Markets
Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Published on: 2026-01-10 12:17:57 - Улправда
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Movers: Why Telomir Pharmaceuticals Inc. stock is recommended by analystsGlobal Markets & Real-Time Market Trend Scan - Улправда
Is Telomir Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Outlook & Advanced Swing Trade Entry Alerts - Улправда
Why retail investors favor Telomir Pharmaceuticals Inc. stockQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - Улправда
Trend Review: Why retail investors favor Telomir Pharmaceuticals Inc stockEarnings Growth Report & Step-by-Step Trade Execution Guides - Bộ Nội Vụ
Can Telomir Pharmaceuticals Inc. stock sustain revenue growthMerger & Acquisition Updates & Build Wealth With Expert Timing Advice - Улправда
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models - The Florida Times-Union
How Telomir Pharmaceuticals Inc. stock reacts to inflationary pressuresLow Risk Investment Ideas & Minimal Investment Portfolio Growth - ulpravda.ru
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models - Investing.com Australia
Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It - Benzinga
Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC - TipRanks
Telomir Pharmaceuticals Reports Positive Preclinical Results for Telomir-1 - TradingView — Track All Markets
Experimental breast cancer drug slows aggressive tumors in animal tests - Stock Titan
Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationOptions Trading Strategies & Start Investing With Free Smart Watchlists - bollywoodhelpline.com
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Lancaster Eagle-Gazette
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened - Defense World
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9%Here's What Happened - MarketBeat
Is Telomir Pharmaceuticals Inc stock oversold or undervaluedRisk Management & Weekly Hot Stock Watchlists - moha.gov.vn
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN
Momentum Shift: What is the fair value of Telomir Pharmaceuticals Inc stock nowPortfolio Profit Report & AI Driven Stock Movement Reports - Bộ Nội Vụ
Telomir Pharmaceuticals sets CEO incentive awards and salary adjustment - Investing.com
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):